Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies

dc.contributor.authorLai, Jeffreyen_AU
dc.contributor.authorClements, Marken_AU
dc.contributor.authorRoddam, Andrew Wen_AU
dc.contributor.authorBanks, Emilyen_AU
dc.contributor.authorLucas, Robynen_AU
dc.date.accessioned2010-09-15T06:23:36Zen_US
dc.date.accessioned2010-12-20T06:03:36Z
dc.date.available2010-09-15T06:23:36Zen_US
dc.date.available2010-12-20T06:03:36Z
dc.date.issued2010-06-11en_US
dc.date.updated2016-02-24T11:16:05Z
dc.description.abstractBACKGROUND: Vitamin D supplementation for fracture prevention is widespread despite conflicting interpretation of relevant randomised controlled trial (RCT) evidence. This study summarises quantitatively the current evidence from RCTs and observational studies regarding vitamin D, parathyroid hormone (PTH) and hip fracture risk. METHODS: We undertook separate meta-analyses of RCTs examining vitamin D supplementation and hip fracture, and observational studies of serum vitamin D status (25-hydroxyvitamin D (25(OH)D) level), PTH and hip fracture. Results from RCTs were combined using the reported hazard ratios/relative risks (RR). Results from case-control studies were combined using the ratio of 25(OH)D and PTH measurements of hip fracture cases compared with controls. Original published studies of vitamin D, PTH and hip fracture were identified through PubMed and Web of Science databases, searches of reference lists and forward citations of key papers. RESULTS: The seven eligible RCTs identified showed no significant difference in hip fracture risk in those randomised to cholecalciferol or ergocalciferol supplementation versus placebo/control (RR = 1.13[95%CI 0.98-1.29]; 801 cases), with no significant difference between trials of <800 IU/day and ≥800 IU/day. The 17 identified case-control studies found 33% lower serum 25(OH)D levels in cases compared to controls, based on 1903 cases. This difference was significantly greater in studies with population-based compared to hospital-based controls (χ2 1 (heterogeneity) = 51.02, p < 0.001) and significant heterogeneity was present overall (χ2 16 (heterogeneity) = 137.9, p < 0.001). Serum PTH levels in hip fracture cases did not differ significantly from controls, based on ten case-control studies with 905 cases (χ2 9 (heterogeneity) = 149.68, p < 0.001). CONCLUSIONS: Neither higher nor lower dose vitamin D supplementation prevented hip fracture. Randomised and observational data on vitamin D and hip fracture appear to differ. The reason for this is unclear; one possible explanation is uncontrolled confounding in observational studies. Post-fracture PTH levels are unrelated to hip fracture risk.
dc.format17 pages
dc.identifier.citationBMC Public Health 10.331 (2010)
dc.identifier.issn1471-2458en_US
dc.identifier.urihttp://hdl.handle.net/10440/1095en_US
dc.identifier.urihttp://digitalcollections.anu.edu.au/handle/10440/1095
dc.publisherBioMed Central Ltd
dc.rights© 2010 Lai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.sourceBMC Public Health
dc.source.urihttp://www.biomedcentral.com/content/pdf/1471-2458-10-331.pdfen_US
dc.source.urihttp://www.biomedcentral.com/1471-2458/10/331en_US
dc.subjectKeywords: 25 hydroxyvitamin D; 25-hydroxyvitamin D; drug derivative; parathyroid hormone; vitamin D; article; blood; comparative study; diet supplementation; female; hip fracture; human; male; meta analysis; middle aged; observation; randomized controlled trial (to
dc.titleHip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies
dc.typeJournal article
dcterms.dateAccepted2010-06-11en_US
local.bibliographicCitation.issue331
local.bibliographicCitation.startpage17
local.contributor.affiliationLai, Jeffrey, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationLucas, Robyn, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationClements, Mark, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationRoddam, Andrew W, University of Oxford
local.contributor.affiliationBanks, Emily, College of Medicine, Biology and Environment, ANU
local.contributor.authoruidu3938863en_US
local.contributor.authoruidu4002313en_US
local.contributor.authoruidu3144615en_US
local.contributor.authoruidE16614en_US
local.contributor.authoruidu4106314en_US
local.identifier.absfor111716en_US
local.identifier.ariespublicationu4637548xPUB125en_US
local.identifier.citationvolume10
local.identifier.doi10.1186/1471-2458-10-331
local.identifier.scopusID2-s2.0-77953315205
local.identifier.thomsonID000281847500001
local.publisher.urlhttp://www.biomedcentral.com/en_US
local.type.statusPublished Versionen_US

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lai_Hip2010.pdf
Size:
1.06 MB
Format:
Adobe Portable Document Format